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Abstract
Corticobasal degeneration typically progresses gradually over 5–7 years from onset till death. Fulminant corticobasal degen-
eration cases with a rapidly progressive course were rarely reported (RP-CBD). This study aimed to investigate their neu-
ropathological characteristics. Of the 124 autopsy-confirmed corticobasal degeneration cases collected from 14 centres, we 
identified 6 RP-CBD cases (4.8%) who died of advanced disease within 3 years of onset. These RP-CBD cases had differ-
ent clinical phenotypes including rapid global cognitive decline (N = 2), corticobasal syndrome (N = 2) and Richardson’s 
syndrome (N = 2). We also studied four corticobasal degeneration cases with an average disease duration of 3 years or less, 
who died of another unrelated illness (Intermediate-CBD). Finally, we selected 12 age-matched corticobasal degeneration 
cases out of a cohort of 110, who had a typical gradually progressive course and reached advanced clinical stage (End-
stage-CBD). Quantitative analysis showed high overall tau burden (p = 0.2) and severe nigral cell loss (p = 0.47) in both the 
RP-CBD and End-stage-CBD groups consistent with advanced pathological changes, while the Intermediate-CBD group 
(mean disease duration = 3 years) had milder changes than End-stage-CBD (p < 0.05). These findings indicated that RP-
CBD cases had already developed advanced pathological changes as those observed in End-stage-CBD cases (mean disease 
duration = 6.7 years), but within a significantly shorter duration (2.5 years; p < 0.001). Subgroup analysis was performed 
to investigate the cellular patterns of tau aggregates in the anterior frontal cortex and caudate by comparing neuronal-to-
astrocytic plaque ratios between six RP-CBD cases, four Intermediate-CBD and 12 age-matched End-stage-CBD. Neuronal-
to-astrocytic plaque ratios of Intermediate-CBD and End-stage-CBD, but not RP-CBD, positively correlated with disease 
duration in both the anterior frontal cortex and caudate (p = 0.02). In contrast to the predominance of astrocytic plaques we 
previously reported in preclinical asymptomatic corticobasal degeneration cases, neuronal tau aggregates predominated in 
RP-CBD exceeding those in Intermediate-CBD (anterior frontal cortex: p < 0.001, caudate: p = 0.001) and End-stage-CBD 
(anterior frontal cortex: p = 0.03, caudate: p = 0.01) as demonstrated by its higher neuronal-to-astrocytic plaque ratios in 
both anterior frontal cortex and caudate. We did not identify any difference in age at onset, any pathogenic tau mutation or 
concomitant pathologies that could have contributed to the rapid progression of these RP-CBD cases. Mild TDP-43 pathol-
ogy was observed in three RP-CBD cases. All RP-CBD cases were men. The MAPT H2 haplotype, known to be protective, 
was identified in one RP-CBD case (17%) and 8 of the matched End-stage-CBD cases (67%). We conclude that RP-CBD 
is a distinct aggressive variant of corticobasal degeneration with characteristic neuropathological substrates resulting in a 
fulminant disease process as evident both clinically and pathologically. Biological factors such as genetic modifiers likely 
play a pivotal role in the RP-CBD variant and should be the subject of future research.
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Introduction
Corticobasal degeneration (CBD) typically has a slow pro-
gressive course with a disease duration ranging from 5 to 
7 years [3]. Autopsy-confirmed CBD cases with disease 
duration of 3 years or less are rare but have been described 
in the literature. A report described a CBD patient who pre-
sented with a 10-month history of rapidly progressive cor-
ticobasal syndrome described as ‘fulminant’ CBD [55]. In 
a small series of 14 CBD cases, one patient had a disease 
duration of 2.5 years [65], while another series of 15 CBD 
cases reported a patient who succumbed to the illness after 
2 years [48].
A phenotypic presentation of corticobasal syndrome 
can be caused by CBD as well as a number of other 
pathologies [42]. On the other hand, clinical presenta-
tions of CBD are heterogeneous and were categorised 
by the latest clinical diagnostic criteria into four main 
phenotypes [3]: corticobasal syndrome, frontal behav-
ioural-spatial syndrome, non-fluent and agrammatic 
variant of primary progressive aphasia, and progressive 
supranuclear palsy syndrome or Richardson’s syndrome. 
These phenotypes encompass a constellation of cogni-
tive, behavioural, language, motor and movement impair-
ments. When a rapidly progressive course is encountered, 
some of these phenotypes may be encompassed under 
the umbrella term of ‘rapidly progressive dementias’ 
[19]. Prion disease, notably Creutzfeldt-Jakob disease, 
is a potential underlying diagnosis in rapidly progres-
sive dementias [19]. Sporadic Creutzfeldt-Jakob disease 
presenting with a pure clinical phenotype of corticoba-
sal syndrome or Richardson’s syndrome has also been 
reported. These cases typically had an aggressive and 
relentless clinical course leading to death in less than 
one year [4, 31, 38, 47, 52, 63]. Genetic Creutzfeldt-Jakob 
disease [45] and Gerstmann–Sträussler–Scheinker disease 
presenting as a subacute progressive supranuclear palsy 
syndrome have also been described [57].
In a retrospective study, Josephs et al. reviewed the Mayo 
Clinic medical records over a 93-month period and identified 
22 autopsy-confirmed cases of rapidly progressive demen-
tias with a survival period of less than 4 years [28]. Eight 
patients (36%) had Creutzfeldt-Jakob disease, 5 (23%) had 
frontotemporal lobar degeneration with motor neuron dis-
ease, 4 (18%) had a tauopathy (2 CBD and 2 progressive 
supranuclear palsy), 3 (14%) had dementia with Lewy bod-
ies and 2 (9%) had Alzheimer’s disease. All patients with 
Creutzfeldt-Jakob disease died in less than 12 months while 
the patients with non-prion neurodegenerative causes of rap-
idly progressive dementias had a survival period of more 
than a year. The disease duration of both of the two CBD 
cases was 3.5 years and those of the two progressive supra-
nuclear palsy cases were 1.5 years and 3.5 years [28]. Other 
diagnoses of rapidly progressive dementias are autoimmune 
and antibody-mediated encephalopathy, infectious, psychiat-
ric, malignant, paraneoplastic, toxic-metabolic and vascular 
conditions [19]. Some of these conditions are potentially 
treatable but under-represented in autopsy-confirmed rapidly 
progressive dementias series [10, 19, 20, 23].
In clinical practice, many patients with neurodegenera-
tive conditions that are typically slowly progressive are 
erroneously referred with a rapidly progressive dementias 
diagnosis. These patients are often found to have had a 
slow natural course over several years that has been unno-
ticed by family members or undiagnosed. The most com-
mon causes for rapid declines in these patients are urinary 
tract infection, pneumonia or an acute metabolic distur-
bance; and more rarely in some patients, the rapid decline 
is part of the natural disease course as illustrated in the 
present study.
The neuropathological characteristics of autopsy-con-
firmed CBD cases with a rapidly progressive course (RP-
CBD) are not known and whether RP-CBD cases are neu-
ropathologically distinct like other reported CBD variants 
warrants investigation [32–34, 41]. In this study, we have 
investigated these research questions by quantitatively ana-
lysing the neuropathological characteristics in six RP-CBD 
cases and comparing them with other CBD groups.
Materials and methods
Case material
As part of a large-scale pathological study on CBD, we 
collected 124 CBD cases from 14 UK, European, Austral-
ian and USA centres. Demographic and clinical data were 
obtained and reviewed by a neurologist (H.L.) while blinded 
to the pathological data. ‘Disease onset’ was defined as the 
month or year in which the patient’s family noticed the first 
neurological symptom that could be associated with a degen-
erative process and ‘disease duration’ referred to the dura-
tion from disease onset until death. Of the 124 CBD cases, 4 
cases (3.2%) were identified as ‘preclinical’, who were clini-
cally asymptomatic and had early CBD pathology. The quan-
titative pathological findings of three such preclinical cases 
have been reported [41]. The 4th preclinical CBD case was 
only identified in one of the collaborating centres after our 
study was published. Six cases from our large CBD cohort 
(4.8%) were identified to have a rapidly progressive clinical 
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course (RP-CBD) with a disease duration of 3 years or less 
from the onset of their first clinical symptoms until reach-
ing an advanced clinical stage. The 3-year disease duration 
threshold was selected as it represented the 10th percentile 
of a bell-shaped normal distribution. This also coincides 
with half of the median survival period of CBD cases in this 
cohort (median = 6 years). Four CBD cases (3.2%) who had 
developed clinical symptoms but died of another unrelated 
concurrent illness before reaching an advanced clinical stage 
were referred to as ‘intermediate’ CBD cases (Int-CBD). 
We hypothesise that, unlike RP-CBD, the Int-CBD cases 
would have had a gradual and slowly progressive illness 
during their entire disease course, had their clinical course 
not been interrupted by another illness leading to death, i.e. 
pulmonary embolism (Int-CBD Case 1), adenocarcinoma 
of the lung (Int-CBD Case 3), and myocardial infarction 
(Int-CBD Case 2 & 4). The remaining 110 cases (88.7%) 
had end-stage CBD (ES-CBD) clinically advanced disease 
following gradual progression of the natural disease course 
and died after reaching an advanced clinical stage.
To confirm the diagnosis, microscopic examination was 
carried out in all cases by a neuropathologist (T.R.). Selected 
cases were also further reviewed by two other neuropatholo-
gists (J.L.H. and E.G.). Cases with known MAPT mutation 
were excluded from the study. All cases in the RP-CBD, 
Int-CBD, and ES-CBD disease groups fulfilled the patho-
logical diagnostic criteria for CBD [15]. This Queen Square 
Brain Bank study was approved by a London Multi-Centre 
Research Ethics Committee and tissue is stored for research 
in the Queen Square Brain Bank for Neurological Disorders 
under a licence from the Human Tissue Authority.
Clinical phenotyping
Cases were assigned a clinical phenotype (corticobasal 
syndrome, Richardson’s syndrome, primary progressive 
aphasia, frontal behavioural-spatial syndrome) following 
the Armstrong criteria [3] whenever clinical data were 
sufficient, otherwise the clinical diagnosis reported by the 
external centres was applied as the clinical phenotype. In 
a large systemic literature review of 210 pathologically 
confirmed CBD cases, Armstrong et al. reported five main 
clinical phenotypes: corticobasal syndrome (37.1%), Rich-
ardson’s syndrome (23.3%), frontotemporal dementia (or 
frontal behavioural-spatial syndrome; 13.8%), Alzheimer’s 
disease-like dementia (8.1%) and primary progressive apha-
sia (4.8%), while others had clinical features of more than 
one phenotype (‘overlap’ phenotype; 5.7%) [3]. In cases 
with unclarified clinical diagnosis and insufficient clinical 
data, the phenotype is designated as ‘undetermined’. Of 
our 120 clinically symptomatic CBD cases, 25 cases had 
corticobasal syndrome [3], 16 had Richardson’s syndrome 
[3], 13 had primary progressive aphasia [3], 20 had frontal 
behavioural-spatial syndrome [3], 18 had overlap pheno-
types, 2 had rapid global cognitive decline, 1 had posterior 
cortical atrophy [14], 4 had predominant gait disorder and/or 
apraxia, and 21 cases had undetermined phenotype.
Neuropathological methods
For cases obtained from external centres, tissue slides or 
paraffin blocks were requested. For internal cases from the 
Queen Square Brain Bank (N = 30), the brains were divided 
in the mid-sagittal plane. One half, chosen randomly, was 
frozen, and the other half immersed and fixed in 10% buff-
ered formalin for 3 weeks before neuropathological exami-
nation. In view of the retrospective and multi-centre nature 
of this study, specification of the sampling of half brain 
using clinical correlations such as hemisphere contralateral 
to the more affected hemi-body was not possible. Tissue 
blocks were taken using the standard Queen Square Brain 
Bank protocol. Eight-µm thick sections were stained with 
haematoxylin and eosin.
Immunohistochemistry with antibodies to the follow-
ing antigens was performed using a standard avidin–bio-
tin method: tau (AT8 clone; Thermo scientific MN1020; 
1:600), 3-repeat tau and 4-repeat tau (gift from Dr Rohan 
de Silva; 1:750), alpha B Crystallin (Leica Biosystems NCL-
ABCrys-512, clone G2JF; 1:3000), glial fibrillary acidic 
protein (IHC-Tek Antibody Diluent, clone GA5 mouse 
anti-human; 1:100), amyloid-β peptide (Biosource interna-
tional, Camarillo, CA, Mouse Dako, clone 6F/3D; 1:100), 
transactive response DNA-binding protein 43 kDa (TDP-43; 
monoclonal; clone 2E2-D3; 1:2000), p62 (BD Transduction 
Labs, 1:200), and α-synuclein (Novocastra; 1:50).
Quantitative analysis of tau load
Twenty brain regions which are known to be affected in 
CBD and whose involvement is predicted to contribute 
to the clinical features were selected: the anterior frontal 
cortex (Brodmann area 9 or prefrontal cortex) grey matter 
and white matter, posterior frontal cortex (Brodmann area 
4 or primary motor cortex) grey and white matter, middle 
temporal gyrus (Brodmann area 21) grey and white mat-
ter, superior parietal lobule (Brodmann area 7) grey and 
white matter, hippocampal formation (CA1-4, granular cell 
layer of the dentate gyrus, subiculum), amygdala, caudate, 
putamen, globus pallidus, subthalamic nucleus, midbrain 
tectum and tegmentum including substantia nigra, pontine 
tegmentum and base, cerebellar dentate nucleus and white 
matter.
Histological AT8 immunolabelled slides were digitized 
on a LEICA SCN400F scanner (LEICA Milton Keynes, 
UK) under a × 20 objective. Slides were viewed and man-
aged in LEICA Slidepath (LEICA Milton Keynes, UK). 
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Brain regions of interest were manually selected and digi-
tally outlined (H.L. and K.D.) using Definiens Developer 
2.3 (Definiens, Munich, Germany). After conversion of 
the red–green–blue (RGB) image to hue-saturation-density 
(HSD) representation [64] giving a measure of brown stain 
intensity at each pixel, a threshold was identified which cap-
tured the two-dimensional area of all AT8 labelled lesions 
(brown) in a test set of images; this same threshold setting 
was used for all cases. For each selected region, the ‘areal 
fraction’, defined by the ratio of the total area occupied by 
the tau-immunoreactive lesions and the entire area of inter-
est, was computed. ‘Regional’ tau load for each brain region 
was expressed as a percentage (areal fraction × 100%) [24]. 
‘Total’ tau load was the sum of tau load in all 20 regions. 
‘Cortical’ grey matter and white matter tau load was the sum 
of tau load of the grey and white matter of the anterior fron-
tal, posterior frontal, temporal and parietal regions. ‘Basal 
ganglia’ tau load was the sum of tau load of the caudate, 
putamen, globus pallidus and subthalamic nucleus.
Cell loss in substantia nigra
Neuronal loss in the substantia nigra pars compacta was 
determined in all 124 CBD cases using a four-tier semi-
quantitative grading system by a neuropathologist (T.R.) 
from grade 0 = no neuronal loss to grade 3 = most severe 
neuronal loss. The substantia nigra was divided for the grad-
ing assessment into five subregions: medial, dorsomedial, 
dorsolateral, ventrolateral and lateral.
Secondary pathologies
The following additional pathologies were systematically 
assessed in all 124 CBD cases: p62-positive neuronal cyto-
plasmic inclusions seen in cases with C9orf72 expansion in 
the hippocampus and cerebellum, cerebral amyloid angiopa-
thy in all cortical blocks, and AT8 and p62 for argyrophilic 
grains in the hippocampus and amygdala [58].
In all cases (N = 124), TDP-43 pathology was assessed in 
the hippocampus and amygdala. Additional TDP-43 staining 
was performed in the midbrain and pons in cases included 
in the subgroup analysis. Previous study by Koga et al. on 
TDP-43 pathology in CBD demonstrated all TDP-43 posi-
tive cases had TDP-43 pathology in either one of the four 
tissue sections: midbrain, subthalamic nucleus, amygdala, 
and pons. Since the subthalamic nucleus is not consistently 
sampled in some cases from external centres, tissue sections 
of the midbrain and pons were chosen for additional screen-
ing to ensure the presence of TDP-43 pathology especially 
in RP-CBD cases, was not underestimated.
The hippocampal formation was assessed for hippocam-
pal sclerosis on haematoxylin and eosin stained histological 
sections [49]. To determine the level of Alzheimer’s disease 
neuropathological change, the ABC score was established 
according to the National Institute on Aging-Alzheimer’s 
Association Guidelines [26]. Additional sections were 
assessed using 3R and 4R tau immunohistochemistry, which 
contributed to the differentiation between Alzheimer-related 
(mixed 3R and 4R tau) and CBD-related neurofibrillary tan-
gle pathology (4R tau).
Subgroup quantitative analysis
For subgroup analysis, 12 ES-CBD cases of different clini-
cal phenotypes (corticobasal syndrome: N = 4, Richardson’s 
syndrome: N = 4, frontal behavioural-spatial syndrome: 
N = 4) were selected as controls based on their age at death 
(mean 68.3 years ± 8.0) which matched those of the RP-
CBD cases (p = 0.5). Only cases with well-documented 
clinical data were chosen. The causes of death of the 12 
ES-CBD cases were septicaemia (N = 3), aspiration pneumo-
nia (N = 3) and ‘progressive deterioration from underlying 
neurodegenerative condition’ (N = 6).
The 4 Int-CBD cases identified in our cohort were 
included as a comparative group because they had the same 
mean disease duration as the RP-CBD cases (Int-CBD: 
3 years ± 1.8 vs. RP-CBD: 2.3 years ± 1.2; p = 0.1) but Int-
CBD cases succumbed to unrelated concurrent illnesses and 
did not reach advanced clinical stage and were hypothesised 
to have an ‘interrupted’ disease course.
Comparisons of variables outlined below were performed 
between 6 RP-CBD, 4 Int-CBD, and 12 selected ES-CBD 
cases.
Cellular lesion types
Quantitative analysis of cellular lesion types of the RP-CBD 
(N = 6), Int-CBD (N = 4), and ES-CBD (N = 12) cases was 
performed using the same methods outlined in our published 
study on preclinical CBD cases [41].
Tau-positive cellular lesions including neuronal lesions 
(neurofibrillary tangles and pretangles) and astrocytic 
plaques were manually counted (H.L.), while neuropil 
threads were graded semi-quantitatively using a four-tier 
scale (by H.L. from grade 0 = absent to grade 3 = severe) 
under a × 20 objective in five random fields in the anterior 
frontal cortical (Brodmann area 9 or prefrontal cortex) grey 
matter and the caudate nucleus.
Coiled body pathology was not included in the quantita-
tive analysis because we previously demonstrated that coiled 
bodies were much less common than other lesion types in 
the cortical white matter and striatum in end-stage cases 
[41]. Sparse coiled body pathology can be obscured in the 
presence of severe tau burden in the cortical white matter.
The anterior frontal cortex and caudate nucleus were 
chosen for this semi-quantitative analysis because these 
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regions were identified as the earliest brain regions affected 
by CBD-tau pathology as observed in the preclinical CBD 
cases [41]. A characteristic astrocytic lesion composed of a 
distinct annular array of tau-positive short stubby processes 
with or without a visible astrocytic nucleus was included as 
an astrocytic plaque in manual counting.
A case lesion score (neuronal lesion score and astrocytic 
plaque score) for each region (anterior frontal cortex and 
caudate nucleus) was determined by the sum of lesion counts 
in all five random fields of the corresponding region. A mean 
lesion score was generated for each disease group (RP-CBD, 
Int-CBD, and ES-CBD) for each region. The ratio between 
mean neuronal lesion score and mean astrocytic plaque score 
was designated as the neuronal-astrocytic plaque ratio in the 
anterior frontal cortex and caudate nucleus for each disease 
group.
Neuronal loss
Neuronal loss, gliosis and microvacuolation were deter-
mined in the frontal, temporal and parietal cortical grey 
matter using a four-tier semi-quantitative grading system by 
a neuropathologist (T.R. from grade 0 = no neuronal loss/
gliosis/ microvacuolation to grade 3 = most severe neuronal 
loss/gliosis/microvacuolation). The amount of balloon neu-
rons identified by alpha B Crystallin immunolabelling was 
graded semi-quantitatively in these cortical regions (T.R. 
from grade 0 = no balloon neurons to grade 3 = frequent 
balloon neurons). Similarly, neuronal loss and gliosis were 
determined semi-quantitatively in the caudate, putamen, 
globus pallidus, subthalamic nucleus, midbrain tectum and 
tegmentum, pontine tegmentum and base, cerebellar dentate 
nucleus and gliosis in the white matter (T.R. from grade 
0 = no neuronal loss and/or gliosis to grade 3 = severe neu-
ronal loss and/or gliosis).
Genetic analysis
DNA was extracted from frozen brain tissue (cerebellum 
or frontal cortex) of all 124 CBD cases. All DNA samples 
were sent to Gerard Schellenberg’s laboratory in University 
of Pennsylvania where whole exome sequencing was per-
formed using Agilent SureSelect Capture v5 (Santa Clara, 
CA, USA), and was sequenced with Illumina HiSeq (San 
Diego, CA, USA). DNA samples of the 6 RP-CBD cases and 
12 ES-CBD control cases selected for subgroup analysis also 
underwent genotyping using the Illumina (San Diego, CA) 
NeuroChip [6]. MAPT mutations covered by the NeuroChip 
were screened. Single nucleotide polymorphism imputation 
was carried out on the NeuroChip data using the Sanger 
Imputation Service to analyse for MAPT H1/H2 haplotype 
and APOE allele.
Statistical analysis
The SPSS 25.0 statistical package (IBM Corporation, 
New York, USA) was used. Log transformation was per-
formed to normalize data when indicated. Student’s t 
test and ANOVA (LSD post-Hoc analysis) were used to 
compare mean tau load  (log10), neuronal loss  (log10) and 
other continuous data. Pearson χ2 test was used to compare 
neuronal-to-astrocytic lesion ratios between CBD disease 
groups.
P-value of 0.05 was used as the threshold for statisti-
cal significance. To correct for multiple comparisons for 
regional tau load and neuronal loss analysis, a p-value 
of 0.0025 was calculated as the threshold for statistical 
significance (= 0.05/number of regions, i.e. 20). To cor-
rect for multiple comparisons for neuronal-to-astrocytic 
plaque ratio between the three disease groups (i.e. RP-
CBD vs. ES-CBD, RP-CBD vs. Int-CBD and Int-CBD 
vs. ES-CBD), a p-value of 0.017 was calculated as the 
threshold for statistical significance (= 0.05/3). Due to the 
small sample sizes of the RP-CBD and Int-CBD groups, 
results without adjustment for multiple comparisons are 
also reported and discussed.
Results
Overview
Of the 124 cases included in our large-scale pathological 
study of CBD, 6 CBD cases (4.8%) had a rapidly progres-
sive course with survival period of 3 years or less after the 
onset of first symptoms. The mean disease duration from 
onset of first symptoms until death of the RP-CBD and 
ES-CBD groups was 2.5 years (range 0.7–3 years; SD 0.9) 
and 6.7 years (range 3.5–14 years; SD 2.3), respectively 
(p < 0.001) (Table 1). There was no difference between the 
mean disease duration of the RP-CBD group and Int-CBD 
group (mean 3.0 years, range 1–5 years; SD 1.8; p = 0.1).
The mean age at death of the Int-CBD group was 
81.5  years, SD 3.0 which was significantly higher 
than those in the ES-CBD group (70.6 years, SD 7.8; 
p = 0.009). This finding indicates that these older Int-CBD 
patients had succumbed to unrelated concurrent illnesses 
before reaching an advanced clinical stage of CBD. Most 
importantly, there was no difference in the mean age at 
onset (p = 0.07) between RP-CBD and ES-CBD groups, 
suggesting that age was not contributory to the short sur-
vival period in the RP-CBD group. All RP-CBD cases 
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were male whereas the female-to-male ratio of ES-CBD 
cases was 1:1.4 (Fisher’s exact test: p = 0.048).
Rapidly progressive CBD (RP‑CBD)
The demographic data of the 6 RP-CBD cases are sum-
marised in Table 2. Their disease duration ranged from 
8 months to 3 years. Two presented with rapid global cog-
nitive decline, and others presented with either rapidly 
progressive corticobasal syndrome (N = 2) or Richardson’s 
syndrome (N = 2). Prion disease was considered as a dif-
ferential diagnosis in 3 cases; one underwent ante-mortem 
brain biopsy (RP-Case 4) and the autopsies of the other 2 
cases (RP-Case 2 & 6) were performed in a mortuary accred-
ited for carrying out post-mortem examinations on high-risk 
cases. Histological examination including negative immu-
nohistochemistry staining of pathological prion protein had 
ruled out prion disease as the underlying diagnosis in all 6 
cases.
We outlined below the clinical summary of RP-Case 2 
as a case illustration. This patient was diagnosed and seen 
by our group (H.L.) in the specialist movement disorders 
clinic at the National Hospital for Neurology and Neurosur-
gery, Queen Square in London and was reviewed frequently 
throughout the disease course until death due to his rapid 
deterioration.
Case illustration (RP‑case 2)
This patient presented to a specialist movement disorders 
clinic with an 18-month history of progressive dysarthria, 
generalised bradykinesia, impaired manual dexterity, hyper-
salivation, freezing of gait and frequent backward falls. His 
children remarked on his impulsivity and poor insights of 
his motor impairment and personality changes. The mild 
improvements in his motor symptoms with Levodopa ther-
apy were only transient. Examination revealed a staring 
gaze with decreased blink rate, vertical supranuclear gaze 
palsy, upright posture, nuchal and limb rigidity, and pos-
tural instability. Magnetic resonance imaging performed 
19 months after symptom onset showed moderate midbrain 
atrophy and generalised atrophy. Dopamine transporter scan 
showed markedly reduced tracer uptake. Neuropsychomet-
ric testing revealed dysfunction in the anterior, subcortical 
and nondominant posterior regions. An initial diagnosis of 
progressive supranuclear palsy was made.
Over the next 12 months, his motor and cognitive func-
tions deteriorated rapidly, and he required assistance for 
most of his daily activities. He was disinhibited verbally and 
physically; he became hypersexual and developed stereotypy 
behaviours such as fiddling with a key ring and counting 
purposelessly. He had daily backward falls resulting in mul-
tiple head injuries and fractures. He was incontinent and 
had significant weight loss due to worsening dysphagia and 
Table 1  Overview of 
demographic data of the rapidly 
progressive CBD (RP-CBD), 
intermediate-CBD (Int-CBD), 
and end-stage CBD (ES-CBD) 
groups
CBD corticobasal degeneration, NA not applicable, SD standard deviation
Disease groups Number 
of cases
Gender (F:M) Mean age 
at onset 
(years ± SD)
Mean age 
at death 
(years ± SD)
Mean dis-
ease duration 
(years ± SD)
Preclinical CBD 4 2:2 NA 76.5 ± 10.7 NA
RP-CBD 6 0:6 70.0 ± 12.0 72.3 ± 12.7 2.5 ± 0.9
Int-CBD 4 1:3 78.5 ± 3.3 81.5 ± 3.0 3.0 ± 1.8
ES-CBD 110 45:65 63.9 ± 7.5 70.6 ± 7.8 6.7 ± 2.3
Table 2  Demographic data of six rapidly progressive CBD (RP-CBD) cases
CBD corticobasal degeneration, CBS corticobasal syndrome, GCD global cognitive decline, RP-CBD rapidly progressive CBD, RS Richardson’s 
syndrome, SD standard deviation
Case no Clinical 
phenotype
Gender Age at onset 
(years)
Age at death 
(years)
Duration 
(years)
Antemortem clinical diag-
nosis of prion disease
Causes of death
RP-Case 1 CBS Male 80 83 3 No Bronchopneumonia
RP-case 2 RS Male 56 59 2.6 Yes Cardiorespiratory failure
RP-case 3 GCD Male 71 73 2 No Bronchopneumonia
RP-case 4 GCD Male 57 57 0.7 Yes Respiratory insufficiency
RP-case 5 CBS Male 70 73 3 No Cardiorespiratory failure
RP-case 6 RS Male 86 89 3 Yes Cardiorespiratory failure
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frequent aspiration. He died 31 months after the onset of his 
first symptoms.
Quantitative analysis of tau load
Total, cortical and basal ganglia tau load
The mean total tau load, cortical grey matter tau load and 
basal ganglia tau load did not differ between the RP-CBD 
and the ES-CBD groups (p > 0.05, Fig. 1). The cortical white 
matter tau load of the RP-CBD group was less than that of 
the ES-CBD group (p = 0.04). On the other hand, the mean 
total tau load, cortical grey and white matter tau load and 
basal ganglia tau load of the Int-CBD group were all less 
than that of the ES-CBD group (p < 0.03).
Regional tau load
Regional tau load of the 20 selected brain regions was deter-
mined (Fig. 2). The tau load was the same between the RP-
CBD and ES-CBD groups in the majority of the regions 
analysed, except in the temporal grey (p = 0.02) and white 
matter (p = 0.01) where the regional tau load was less in the 
RP-CBD group. When comparing regional tau load between 
the Int-CBD and ES-CBD groups, the tau load in all regions 
was numerically less in the Int-CBD group. Tau load in the 
following regions was less in the Int-CBD group than in 
the ES-CBD group with statistical significance (p < 0.05): 
anterior frontal grey and white matter, temporal grey and 
white matter, caudate, putamen, and subthalamic nucleus. 
After adjustment for multiple comparisons, the anterior fron-
tal white matter was the only region that showed statistical 
significance when comparing regional tau load between Int-
CBD and ES-CBD groups (p = 0.02).
Cell loss in substantia nigra
Semi-quantitative assessment of cell loss using a four-tier 
grading system showed that the mean nigral cell loss in the 
RP-CBD (N = 6) and ES-CBD (N = 110) groups was moder-
ate (grade 2) to severe (grade 3) in all five substantia nigra 
subregions and there was no significant difference between 
the two groups (p > 0.3; Fig. 3). In contrast, the mean cell 
loss in the Int-CBD group was only mild (grade 1) in all 
nigral subregions and was significantly less severe in all sub-
regions when compared with the ES-CBD group (p < 0.03). 
After adjusting for multiple comparisons, the mean cell loss 
in the medial and dorsomedial subregions remained signifi-
cantly milder in the Int-CBD group than the ES-CBD group 
(p < 0.001). Similarly, after adjusting for multiple compari-
sons, cell loss in the medial nigral subregion was signifi-
cantly less severe in the Int-CBD group than in the RP-CBD 
group (p < 0.01).
Secondary pathologies
No difference was found in the presence of hippocam-
pal sclerosis (RP-CBD: 1 in 6 (17%), ES-CBD: 10 in 
110 (9%); χ2 test: p = 0.46), argyrophilic grain disease 
Fig. 1  Mean Total, Cortical Grey Matter, Cortical White Matter and 
Basal Ganglia Tau Load of the Intermediate (Int-CBD), Rapidly 
Progressive (RP-CBD) and End-Stage (ES-CBD) Groups. All the 
illustrated tau load measurements of the intermediate group were 
significantly less than the end-stage group (ANOVA, LSD post-Hoc 
analysis; p < 0.05). All tau load measurements were the same statis-
tically between the rapidly progressive and end-stage CBD groups, 
except there was less cortical white matter tau load in the rapidly 
progressive group than in the end-stage group (ANOVA, LSD post-
Hoc analysis; p = 0.04). Error bars represent one standard error of the 
mean (SEM)
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(RP-CBD: 3 in 6 (50%), ES-CBD: 70 in 110 (64%); χ2 
test: p = 0.67) between RP-CBD and ES-CBD cases. Mild 
hippocampal TDP-43 pathology was observed in only two 
RP-CBD cases (Case 5: corticobasal syndrome phenotype 
and Case 6: Richardson’s syndrome). Of the 11 cases with 
hippocampal sclerosis, nine had TDP-43 pathology inclu-
sive of a RP-CBD case (RP-Case 5). No difference in the 
severity of Aβ Thal phase, Braak and Braak neurofibril-
lary tau stage, CERAD neuritic plaque score and cerebral 
amyloid angiopathy was identified between RP-CBD and 
ES-CBD cases (Mann Whitney test; p > 0.4). C9orf72 
expansion mutation-related inclusions were not identified 
in any of the 124 cases in the present cohort.
Secondary pathologies may influence the phenotypic 
presentation and disease course of neurodegenerative 
tauopathies [29, 32, 34, 43, 60, 67]. Therefore, it is note-
worthy that concomitant pathologies were not contributary 
to the rapid progression in RP-CBD (Table 3).
TDP‑43 pathology
No difference was identified in the presence of TDP-43 
pathology (RP-CBD: 3 in 6 (50%), ES-CBD: 29 in 110 
(26%); Fisher’s exact test: p = 0.35) between RP-CBD and 
ES-CBD cases.
Among the three TDP-43 positive RP-CBD cases, 
two cases had mild TDP-43 pathology in the hippocam-
pus and amygdala (RP-5, RP-6) and one case had mild 
TDP-43 pathology in the pontine tegmentum (RP-3), who 
presented with rapid global cognitive decline without 
any record of having a downgaze palsy. CBD cases with 
a Richardson’s syndrome phenotype was not more com-
mon in the positive TDP-43 or severe TDP-43 groups (χ2/
Fisher’s exact test: p > 0.5).
Interestingly, tau burden in the olivopontocerebellar 
system was more severe in the TDP-43 positive group 
Fig. 2  Mean Regional Tau Load of the Intermediate (Int-CBD), Rap-
idly Progressive (RP-CBD) and End-Stage (ES-CBD) Groups. Mean 
regional tau load in the anterior frontal grey and white matter, tempo-
ral grey and white matter, caudate, putamen, and subthalamic nucleus 
were significantly less in the Int-CBD group than in the ES-CBD 
group (ANOVA, LSD post-Hoc analysis; p < 0.05). Mean regional 
tau load in the temporal grey and white matter was significantly 
less in the RP-CBD group when compared with the ES-CBD group 
(ANOVA, LSD post-Hoc analysis; p < 0.05). *Mean regional tau 
load in the anterior frontal white matter was the only region showing 
significant difference between the Int-CBD and ES-CBD group after 
adjustment for multiple comparisons (p = 0.001). Error bars represent 
one standard error of the mean (SEM). AFG anterior frontal grey 
matter, AFW anterior frontal white matter, AMG amygdala, CAU cau-
date, CDN cerebellar dentate nucleus, CWM cerebellar white matter, 
GLP globus pallidus, HIP hippocampus, MTC midbrain tectum, MTG 
midbrain tegmentum, PBS pontine base, PFG posterior frontal grey 
matter, PFW posterior frontal white matter, PRG parietal grey matter, 
PRW parietal white matter, PTG pontine tegmentum, PUT putamen, 
STN subthalamic nucleus, TMG temporal grey matter, TMW temporal 
white matter
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(p = 0.02), consistent with the study findings by Koga 
et al. [32].
Subgroup quantitative analysis
For subgroup analysis, 12 ES-CBD cases were selected 
as age-matched controls. Quantitative analysis on cellular 
lesion type and neuronal loss were compared between the 
RP-CBD (N = 6), Int-CBD (N = 4) and ES-CBD (N = 12) 
groups. No difference was found in the presence/severity 
of TDP-43 pathology between the RP-CBD, Int-CBD, and 
ES-CBD groups in the subgroup analysis (p = 0.28).
Cellular lesion types
Quantitative analysis was performed to study the lesion 
types affected by tau pathology in the anterior frontal cor-
tex and caudate. RP-CBD cases had more neuropil thread 
pathology in the caudate than that of ES-CBD cases with 
borderline significance (p = 0.05), while no difference in 
neuropil thread pathology was found in the anterior frontal 
cortex between the two groups (p = 0.47). Numerically, the 
RP-CBD group had the highest mean neuronal lesion score 
(anterior frontal cortex: 73, caudate: 39) followed by the 
ES-CBD (anterior frontal cortex: 70, caudate: 26) and Int-
CBD groups (anterior frontal cortex: 47, caudate: 33). As for 
astrocytic plaques, the Int-CBD group had the highest mean 
Fig. 3  Proposed Pathological Progression of Different CBD Disease 
Groups. Top panels illustrate increasing total tau load and severity of 
nigral cell loss as the disease progresses from preclinical to interme-
diate, and to end-stage disease. No significant differences in total tau 
load and severity of nigral cell loss were identified between the rap-
idly progressive and end-stage groups. The bottom panel illustrates 
that the preclinical, intermediate and end-stage groups probably fol-
low the same trajectory of disease progression based on our quantita-
tive data above, whereas the rapidly progressive group demonstrates a 
more aggressive disease course with their pathological changes reach-
ing the same level of severity as the end-stage group within 3 years or 
less after symptom onset. Notably, the mean disease duration of the 
Int-CBD and RP-CBD groups did not differ statistically but the sever-
ity of pathological changes in the Int-CBD group were significantly 
milder
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score (anterior frontal cortex: 33, caudate: 29), followed by 
the ES-CBD group (anterior frontal cortex: 23, caudate: 17); 
RP-CBD group had the least number of astrocytic plaques 
(anterior frontal cortex: 10, caudate: 7).
The neuronal-to-astrocytic plaque ratios of the RP-CBD 
group in the anterior frontal cortex (7.5) and caudate (5.6) 
were significantly greater than those of the ES-CBD (anterior 
frontal cortex: 3.0, caudate: 1.5) and Int-CBD groups (ante-
rior frontal cortex: 1.4, caudate: 1.1) (p < 0.05; Fig. 4). These 
findings indicate that the RP-CBD group had a proportion-
ally higher number of neuronal lesions than astrocytic plaques 
when compared with the ES-CBD (χ2 test; anterior frontal 
cortex: p = 0.03, caudate; p = 0.01) and Int-CBD groups (χ2 
test; anterior frontal cortex: p < 0.001, caudate; p = 0.001). 
When compared between the ES-CBD and Int-CBD groups, 
the neuronal-to-astrocytic plaque ratio in the anterior frontal 
cortex was greater in ES-CBD than in Int-CBD in the ante-
rior frontal cortex (χ2 test; p = 0.02), but no difference was 
found in the caudate (χ2 test; p = 0.46). Following correction 
for multiple comparisons, statistical significance was achieved 
for RP-CBD vs. ES-CBD in the caudate and RP-CBD vs. 
Int-CBD in both regions. Among the ES-CBD and Int-CBD 
cases, there was a significant positive correlation between 
neuronal-to-astrocytic plaque ratio and disease duration in 
the anterior frontal cortex and caudate (both regions: Pear-
son’s coefficient = 0.6; p = 0.02). No correlation was identified 
in the RP-CBD cases. These findings suggest a progressive 
increase in neuronal-to-astrocytic plaque ratio in both exam-
ined regions as the disease advances.
Neuronal loss
Semi-quantitative assessment of neuronal loss, gliosis, 
microvacuolation and the amount of balloon neurons was 
performed in anterior frontal, temporal and parietal cortical 
regions in the RP-CBD, Int-CBD, and ES-CBD groups. No 
differences in these parameters were identified in these corti-
cal regions between the three groups, except that neuronal 
loss in the parietal cortex was more severe in the ES-CBD 
group than in the RP-CBD group (p = 0.049).
Similarly, neuronal loss and gliosis in other selected brain 
regions were analysed semi-quantitatively. These parameters 
did not differ significantly between the three groups in the 
following regions: caudate, putamen, globus pallidus, sub-
thalamic nucleus, midbrain tectum and tegmentum, pontine 
tegmentum and base, cerebellar dentate nucleus and white 
matter. The only significant difference identified was that 
gliosis in the caudate nucleus was more severe in the ES-
CBD group than in the Int-CBD group (p = 0.02). After 
adjusting for multiple comparisons, no significant difference 
in these variables was found when compared between the 
three groups.
Genetic analysis
No known pathogenic mutations of the MAPT gene were 
identified in the present cohort of 124 pathologically con-
firmed CBD cases including the six RP-CBD cases. A 
significantly greater proportion of ES-CBD cases (H1H1: 
N = 4, H1H2: N = 8) carried the H2 haplotype, known to be 
a protective factor, when compared with the RP-CBD group 
(H1H1: N = 5, H1H2: N = 1; Fisher’s exact: p < 0.001) [9, 
25]. There was no difference in the distribution of MAPT 
H1/H1 haplotype between TDP-43 positive or negative 
group (χ2: p = 0.26). APOEɛ4 allele was identified in one 
case in each of the RP-CBD (Case 5) and ES-CBD groups 
(Fisher’s exact: p = 0.55).
Fig. 4  Neuronal-To-Astrocytic Plaque Ratios of the Intermediate 
(Int-CBD), Rapidly Progressive (RP-CBD) and End-Stage (ES-
CBD) Groups of the Anterior Frontal Cortex and Caudate Nucleus. 
The ratios for both regions in the RP-CBD group were significantly 
greater than the Int-CBD and ES-CBD groups, indicating proportion-
ally higher number of neuronal lesions (neurofibrillary tangles and 
pretangles) than astrocytic plaques in RP-CBD cases
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Discussion
Of the 124 CBD cases included in our CBD neuropatho-
logical study, 6 (4.8%) had well-documented evidence 
of a rapidly progressive clinical course and reached an 
advanced clinical stage within 3 years or less after the 
first symptom onset. These RP-CBD cases had advanced 
pathological changes as demonstrated by the severity of 
their overall tau burden and nigral cell loss. Neuronal tau 
lesions rather than astrocytic plaques were predominant in 
the RP-CBD variant indicating a distinct cellular vulner-
ability that differs from other CBD disease subgroups. No 
other factors such as age at onset, concomitant pathologies 
or pathogenic tau mutations were found to be contributory 
to the rapid progressive course of these RP-CBD cases. 
Our findings suggest that RP-CBD is a distinct fulminant 
CBD variant that has an aggressive disease process result-
ing in rapid progression both clinically and pathologically.
Tau burden
The level of pathological tau burden is a good measure of 
the neurodegenerative process in both Alzheimer’s disease 
and primary tauopathies [8, 22]. Despite the significantly 
shorter disease duration, RP-CBD cases had the same 
level of tau burden as those in the ES-CBD group. While 
tau burden in the cortical grey matter and basal ganglia 
was similar in the two groups, cortical white matter tau 
load was less in the RP-CBD group, which suggests that 
CBD-tau accumulation in the cortical white matter may 
lag behind tau accumulation in other brain regions in RP-
CBD cases. Region-to-region comparison showed that tau 
burden in the 20 selected brain regions was the same in 
the RP-CBD and ES-CBD groups, except in the temporal 
cortical grey and white matter where the amount of tau 
was significantly less in the RP-CBD group. This suggests 
that the temporal cortex is either relatively preserved in 
RP-CBD or that it is one of the latest regions to be severely 
affected by CBD-tau pathology in RP-CBD. Within the 
basal ganglia circuitry, the highest regional tau load 
was identified in the caudate, putamen, globus pallidus 
and subthalamic nucleus in the ES-CBD group, and RP-
CBD cases also had the same level of tau burden in these 
severely affected regions. Brain regions identified to have 
relatively less tau burden when compared with ES-CBD 
(i.e. cortical white matter and temporal cortical grey and 
white matter) most likely did not play a primary role in 
contributing to the rapid clinical deterioration in RP-CBD. 
In other words, these regions may be considered as ‘non-
strategic’ regional correlates, contrasting with the frontal 
and parietal cortices and basal ganglia circuitry which are 
‘strategic’ brain regions where a comparable extent of 
severe tau burden was identified in both RP-CBD and ES-
CBD groups. The hypothesis of the temporal lobe being a 
non-strategic region may be further corroborated in other 
neurodegenerative conditions. For instance, semantic vari-
ant of primary progressive aphasia, characterised by pre-
dominant temporal lobe involvement and TDP-43 Type 
C pathology, tends to have longer disease duration and is 
considered a more benign form of frontotemporal lobar 
degeneration [37, 46].
Cell loss in the substantia nigra
Studies by our group and others have shown that the substan-
tia nigra is typically preserved in early CBD cases and nigral 
cell loss becomes more severe as the disease progresses [41, 
50, 51, 53]. Again, despite the shorter mean disease dura-
tion, RP-CBD cases had the same level of nigral cell loss 
as ES-CBD, while Int-CBD had milder nigral cell loss than 
both RP-CBD and ES-CBD.
Preclinical CBD
Previously, we reported the neuropathological characteris-
tics of three clinically asymptomatic cases who were found 
to have early CBD pathology at post-mortem [41]. These 
preclinical CBD cases provided valuable insights into the 
regional, neural network and cellular vulnerability at the 
earliest disease process of CBD. Although their overall tau 
burden was nine times less than that of the ES-CBD cases 
(Fig. 5), tau aggregates were already widespread in brain 
regions typically affected in ES-CBD [41]. The substan-
tia nigra in preclinical cases was preserved [41] contrast-
ing with the moderate to severe nigral cell loss in ES-CBD 
(Fig. 3). Additional analysis also showed that Int-CBD had 
more severe regional nigral cell loss than preclinical CBD 
(N = 4) with borderline significance in 4 of 5 subregions 
studied (medial: p = 0.08, dorsomedial: p = 0.08, dorsolat-
eral: p = 0.07 and ventrolateral: p = 0.07). Astrocytic plaques 
were the predominant tau lesion in preclinical CBD sug-
gesting that CBD may begin as a primary astrogliopathy 
although neuronal lesions eventually predominate as the dis-
ease process advances [41]. This proposed shift of cellular 
vulnerability to tau accumulation with disease progression 
is also supported by our findings of the higher neuronal-to-
astrocytic plaque ratio in ES-CBD (3.1) than in Int-CBD 
(1.4) in anterior frontal cortex (Fig. 4).
Increasing evidence suggests that glial activation and 
chronic neuroinflammation play a causal role in ageing 
and neurodegeneration [39]. Activated astrocytes and 
microglia and elevated proinflammatory markers can be 
demonstrated in tauopathies [54]. Thorn-shaped astrocytes 
commonly observed in the brains of cognitively normal 
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elderly and primary tauopathies are collectively referred to 
as age-related tau astrogliopathy (ARTAG) [36]. Whether 
the primary role of astrocytic tau in ARTAG and preclini-
cal CBD is pathogenic or protective remains elusive. Nev-
ertheless, these observations indicate that glial cells may 
be a useful target for early diagnosis using neuroimaging 
and molecular-based therapy [54].
Intermediate‑CBD
In the present series, we included an ‘intermediate’ CBD 
group (Int-CBD). These Int-CBD patients had developed 
CBD and, because of their older age, were at higher risk 
of having other medical conditions such as malignancy or 
ischaemic heart disease and had succumbed to these ill-
nesses before reaching an advanced clinical stage of CBD. 
We hypothesised that their pathological progression was 
‘interrupted’ and that their pathological features most 
likely represent an ‘intermediate’ disease stage. These 
four Int-CBD cases were included in the present study 
as a ‘duration-control’ group as they had the same mean 
disease duration as RP-CBD. Comparing the findings 
of the Int-CBD, RP-CBD, and ES-CBD groups allowed 
us to conclude that the features of RP-CBD were truly 
their distinct pathological substrates rather than shorter 
disease duration. We demonstrated the tau burden in all 
brain regions was less severe in Int-CBD than in ES-CBD 
group (Fig. 2). The mean nigral cell loss in the Int-CBD 
group was milder (grade 1) in all nigral subregions than 
RP-CBD and ES-CBD, both of which demonstrated mod-
erate (grade 2) to severe (grade 3) nigral cell loss (Fig. 3). 
Overall, these findings indicated that the pathological 
changes of the preclinical, Int-CBD, ES-CBD cases fol-
lowed the same trajectory of disease progression and that 
this differed from the distinctly aggressive disease course 
of RP-CBD (Fig. 3).
Cortical cell loss, gliosis, and microvacuolation 
in CBD are time‑dependent changes
Neuropathological examination of neuronal loss, gliosis, and 
microvacuolation demonstrated a range of severity in the 
Int-CBD, RP-CBD, and ES-CBD groups. In some ES-CBD 
cases, the frontal and parietal cortices showed advanced 
changes exceeding the severity of those observed in Int-
CBD. In preclinical CBD cases, no cell loss or gliosis was 
seen in the frontal, parietal and temporal cortices, striatum 
and subthalamic nucleus [41].
Based on our observations, we suggest that the neuronal 
loss, gliosis and microvacuolation are time-dependent 
changes. Their regional distribution and severity are also 
phenotype-dependent, as evidenced by the findings of previ-
ous clinicopathological and neuroimaging studies [35]. For 
instance, corticobasal syndrome phenotype demonstrates 
more extensive frontal and parietal cortical neuronal loss 
when compared with RS phenotype [33].
In our subgroup analysis, 12 ES-CBD cases of different 
clinical phenotypes (corticobasal syndrome: N = 4, Richard-
son’s syndrome: N = 4, frontal behavioural-spatial syndrome: 
N = 4) were selected as controls for the subgroup analysis but 
the number of cases representing each phenotype remained 
small. The lack of significant statistical difference in these 
parameters between the Int-CBD, RP-CBD and ES-CBD 
groups may be due to their small sample sizes.
Distinct cellular vulnerability of RP‑CBD
Since the tau load varies between regions, cases and dis-
ease groups, we devised the neuronal-to-astrocytic plaque 
ratio as a measure of the relative frequency and distribution 
of the cellular lesion types. The anterior frontal cortex and 
caudate nucleus, the two regions proposed to be the earliest 
regions affected by CBD-tau pathology [41], were selected 
for quantitative subgroup analysis. We previously demon-
strated that astrocytic plaques predominated the preclinical 
Fig. 5  Tau Immunohistochemistry (AT8) Sections of Preclinical (Case 1; Ling et al. Brain 2016), Intermediate and Rapidly Progressive (RP-
Case 4) and End-Stage CBD (ES-Case 11) Cases (× 10 objective)
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cases in these two regions in contrast to ES-CBD cases, in 
which neuronal tau lesions were predominant [41]. In the 
present study, the positive correlation between neuronal-to-
astrocytic plaque ratios and disease duration demonstrated 
among the ES-CBD and Int-CBD cases in both the anterior 
frontal cortex and caudate further corroborates the notion 
that neuronal tau lesions become more predominant in rela-
tion to astrocytic plaques as the disease progresses.
Intriguingly, cellular vulnerability to abnormal tau accu-
mulation in RP-CBD is distinctly different from other dis-
ease groups and in a manner opposite to preclinical cases. 
The neuronal-to-astrocytic plaque ratio in both the anterior 
frontal cortex and caudate nucleus was significantly higher in 
RP-CBD (anterior frontal: 7.5, caudate: 5.6) than in Int-CBD 
(anterior frontal: 1.4; p < 0.001) (caudate: 1.1; p = 0.001) 
and ES-CBD (anterior frontal: 3.0; p = 0.03) (caudate: 1.5; 
p = 0.01). This finding indicates that neuronal lesions were 
the predominant tau lesion type in the RP-CBD group with 
5–7 times more neuronal lesions than astrocytic plaques pre-
sent in the examined regions. While the total tau burden and 
neuronal loss were similar between the RP-CBD and ES-
CBD groups, RP-CBD had the highest mean neuronal lesion 
score. Accumulation of hyperphosphorylated tau in neurons 
leads to neuronal dysfunction and eventually neuronal death 
[5]. Previous studies in Alzheimer’s disease and primary 
tauopathies demonstrated a dose-dependent clinico-patho-
logical correlation between neuronal tau accumulation and 
clinical dysfunction [5, 7, 40, 66]. Abnormal tau accumula-
tion in selectively vulnerable neurons in RP-CBD probably 
cause accelerated neuronal dysfunction. We hypothesise that 
the predominant neuronal tau lesions observed in RP-CBD 
most likely contributed as the pathological substrate of their 
aggressive clinical disease course.
Is RP‑CBD a distinct aggressive variant of CBD?
The concept of different ‘prion-like strains’ of tau aggre-
gates has been consolidated by the demonstration that the 
inoculation of transgenic tau mice with various tau strains 
causes strain-specific intracellular pathology in distinct 
cell types and brain regions following specific neural net-
work connections as well as inducing different rates of 
network propagation [2, 12, 21, 22, 59]. This concept is 
further underpinned by recent cryo-electron microscopy 
studies demonstrating distinct conformers of assembled 
tau are responsible for different tauopathies [16-18]. Fur-
thermore, Kaufman et al. suggested that strains alone were 
accountable for the diverse neuropathological presenta-
tion of human tauopathies [30]. The potential association 
between strains and clinical progression of neurodegen-
erative diseases is also described in other misfolded pro-
teins such as amyloid-β. A study of rapidly progressive 
Alzheimer’s disease cases reported a correlation with the 
levels of amyloid-β42 with distinct structural characteris-
tics, suggesting a possible mechanistic link between con-
formers and their aggressive clinical disease course [13].
Our systemic analysis suggests that the preclinical, Int-
CBD and ES-CBD groups most likely follow the same tra-
jectory of disease progression, while RP-CBD is a distinct 
variant characterised by rapid clinical and pathological 
progression (Fig. 3). It seems reasonable to hypothesise 
that RP-CBD cases are associated with a specific tau 
‘strain’, which governs their rapid disease process result-
ing in the development of advanced neuropathological 
changes within a very short timeframe. Further investiga-
tions are warranted to confirm this hypothesis.
CBD with severe TDP-43 pathologies was also pro-
posed as a distinct CBD variant characterized by a Rich-
ardson’s syndrome clinical phenotype and severe tau 
pathology in the olivopontocerebellar system [32, 34, 
62, 67]. Likewise, the findings of the present series also 
showed that the presence of TDP-43 pathology was asso-
ciated with greater tau burden in the olivopontocerebellar 
system. Importantly, mild TDP-43 pathology was observed 
in 3 of the 6 RP-CBD cases and the proportion of TDP-43 
positive cases did not differ from those in ES-CBD (29 out 
of 110 cases). We can conclude that the aggressive disease 
course of the RP-CBD variant could not have been attrib-
uted to additional TDP-43 pathology. Moreover, we did 
not identify any significant difference in other secondary 
pathologies between the RP-CBD and ES-CBD disease 
groups.
The clinical phenotypes of the six RP-CBD cases 
were not limited to one specific phenotype: two cases 
had rapid global cognitive decline, two had corticobasal 
syndrome and the other two had Richardson’s syndrome. 
The spectrum of clinical phenotypes in RP-CBD indicates 
that selective vulnerability in this distinct CBD variant 
involves a range of neural networks. Increasing evidence 
indicates that the molecular basis for selective vulnerabil-
ity underlying clinical phenotypes may be determined by 
differences in tau strains and, in part, genetic variants [27, 
59]. It is noteworthy that all 6 RP-CBD cases were male. 
MAPT H2 haplotype is known to be protective and was 
found in only one RP-CBD case [9, 25], which is likely to 
be one of the contributing factors to the aggressive disease 
process in RP-CBD. An intronic variant of the tripartite 
motif-containing protein 11 (TRIM11) has been linked to 
the classic and more aggressive phenotype of progressive 
supranuclear palsy, Richardson’s syndrome [27]. TRIM11 
is predominantly expressed in the neurons in the basal 
ganglia and cerebellum [27]. Whether TRIM11 is also a 
genetic modifier of CBD phenotypes and variants such as 
RP-CBD should be the subject of future research.
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Conclusions
This is the first study to report the pathological substrates 
of RP-CBD. We propose that fulminant CBD is a distinct 
clinicopathological CBD variant, likely to be associated 
with a specific tau ‘strain’. RP-CBD comprised 5% of our 
CBD cohort. The identification of rapid progressors is par-
ticularly important for therapeutic trials as their skewed 
representation in the treatment arms may potentially con-
found the interpretation of treatment outcome [61]. Two 
distinct patterns of decline, fast and slow, were reported in 
Alzheimer’s disease [61], which has been posed as a chal-
lenge in the quest for an effective disease-modifying treat-
ment [11, 44]. The recent finding of a positive correlation 
between neurofilament light chain level in cerebrospinal 
fluid and disease progression rate in progressive supra-
nuclear palsy, Alzheimer’s disease, dementia with Lewy 
bodies and frontotemporal lobar degeneration [1, 56] is a 
promising start to understand the underlying pathophysiol-
ogy, and to identify accurate biomarkers and genetic modi-
fiers of rapid progressors in neurodegenerative diseases 
such as fulminant CBD.
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